V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016941 | 160013488 | null | 64 | Palliative (P) | 2019-04-17 | 2019-05-01 | Doxorubicin + Ifosfamide | 02 | N | NB BEACON TEMOZOLOMIDE AND TOPOTECAN | 100856999 |
| 160016946 | 160013489 | 1.82 | 54.9 | null | 2019-01-29 | 2019-02-27 | ETOPOSIDE + IFOSFAMIDE | 02 | null | NIRAPARIB | 100193304 |
| 160016948 | 160013490 | null | 64.3 | Curative (C) | 2017-07-14 | 2017-07-14 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | NIRAPARIB | 101428663 |
| 160016951 | 160013491 | 1.72 | 64.25 | null | 2017-11-27 | 2017-12-04 | EW EuroEwing 2012 Arm A VAI | 02 | null | OLAPARIB | 101793839 |
| 160016952 | 160013492 | 1.75 | 67.6 | null | 2018-04-05 | 2018-07-16 | DACARBAZINE + GEMCITABINE | 2 | null | RITUXIMAB + VENETOCLAX | 100773637 |
| 160016955 | 160013494 | 1.58 | 70.6 | Curative (C) | 2018-09-30 | 2018-10-05 | Ifosfamide | 02 | Y | STS NON-RHABDO EPSSG 2005 IVA | 101863220 |
| 160016959 | 160013495 | null | 87 | Palliative (P) | null | 2019-07-14 | NB HRNBL-1 ch14.18/CHO only (trial) | 02 | null | IFOSFAMIDE | 100659204 |
| 160016962 | 160013496 | 1.56 | 62.3 | null | 2019-02-12 | 2019-05-30 | EW EuroEwing 2012 Arm A VAI | null | null | ETOPOSIDE | 100095691 |
| 160016965 | 160013497 | 1.28 | 0 | Curative (C) | 2016-07-13 | 2017-05-23 | CARBOPLATIN + ETOPOSIDE | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100019609 |
| 160016967 | 160013498 | 0 | 0 | Adjuvant (A) | 2017-01-24 | 2017-04-18 | Cyclophosphamide oral | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 101201506 |
| 160016969 | 160013499 | 1.8 | 62.3 | null | 2019-03-15 | 2019-05-08 | GEMCITABINE | Y | null | TEMOZOLOMIDE | 100282628 |
| 160016971 | 160013500 | 1.67 | 46.9 | null | 2019-07-30 | 2019-10-08 | GEMCITABINE | 01 | null | ERIBULIN | 100977599 |
| 160016975 | 160013501 | 1.55 | 101.9 | Curative (C) | 2019-01-14 | 2019-02-06 | Etoposide oral | 02 | N | LENALIDOMIDE | 100761456 |
| 160016978 | 160013502 | 0 | 63.9 | null | 2016-01-12 | 2016-07-26 | ETOP 13-18 BEAT-meso Trial | N | null | STS RHABDO RMS 2005 VIN CYCLO | 101383967 |
| 160016979 | 160013503 | 1.64 | 109 | 02 | 2021-03-11 | 2021-03-26 | ATOMIC-MESO TRIAL | N | N | CYCLOPHOSPHAMIDE | 101266518 |
| 160016986 | 160013504 | 1.63 | 64.2 | Palliative (P) | null | 2018-09-09 | CYCLOPHOSPHAMIDE | 02 | null | AFATINIB | 100200365 |
| 160016988 | 160013505 | 1.8 | 70.7 | null | 2017-10-15 | 2019-01-26 | GEMCITABINE | 02 | null | EW EUROEWING 2012 ARM B VC | 100910350 |
| 160016990 | 160013506 | 1.64 | 74 | null | 2020-08-11 | 2021-04-22 | Niraparib | N | null | PEMETREXED | 101822042 |
| 160016991 | 160013507 | 1.84 | 96.6 | null | 2015-01-04 | 2015-01-05 | Bevacizumab+Carbo+Pacliaxel | 02 | null | PEMBROLIZUMAB | 101128729 |
| 160016993 | 160013508 | 1.95 | 109.6 | Palliative (P) | 2017-02-03 | 2017-02-03 | Ifosfamide | 02 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 100212183 |
| 160016994 | 160013509 | 1.64 | 93.7 | null | 2017-05-17 | 2017-06-08 | CARBOPLATIN + ETOPOSIDE | N | N | IFOSFAMIDE | 101183197 |
| 160016996 | 160013510 | 1.7 | 83.3 | Curative (C) | 2019-12-30 | 2020-04-07 | EW EuroEwing 2012 Arm B IE | 01 | null | PEMBROLIZUMAB | 100086284 |
| 160017000 | 160013511 | 1.75 | 79.05 | Palliative (P) | null | 2018-03-10 | Olaparib | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101514865 |
| 160017008 | 160013513 | 1.74 | 71 | Palliative (P) | 2020-07-17 | 2020-07-27 | EW EuroEwing 2012 Arm B IE | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 100090692 |
| 160017009 | 160013514 | 1.64 | 95.2 | Curative (C) | 2019-07-09 | 2019-07-16 | ETOP 13-18 BEAT-meso Trial | 02 | null | BEVACIZUMAB + CARBO + PACLITAXEL | 101316985 |
| 160017011 | 160013515 | 1.58 | null | Curative (C) | 2018-07-04 | 2018-07-04 | Doxorubicin + Ifosfamide | 2 | N | CYCLOPHOSPHAMIDE | 100970885 |
| 160017014 | 160013516 | 1.74 | 19.9 | 03 | 2016-02-20 | 2016-04-18 | Pemetrexed | 02 | N | CAV | 101467040 |
| 160017018 | 160013517 | 1.7 | 73 | 03 | 2017-09-23 | 2017-10-01 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | CARBOPLATIN + LIPOSOMAL DOX | 101215625 |
| 160017019 | 160013518 | 0 | 79.95 | null | 2018-03-13 | 2018-03-27 | Niraparib | 02 | null | CEDIRANIB | 100745063 |
| 160017020 | 160013519 | 1.89 | 66.8 | Curative (C) | 2019-04-10 | 2019-05-23 | EW Rel rEECur Gemcitabine/Docetaxel + GCSF | 2 | N | CYCLOPHOSPHAMIDE | 101741365 |
| 160017024 | 160013520 | 1.67 | 11.6 | null | 2017-06-05 | 2017-07-28 | Rucaparib | null | null | IVA | 101513533 |
| 160017026 | 160013521 | 1.87 | 86.8 | null | 2018-06-23 | 2018-06-23 | VINCRISTINE | Y | N | STS RHABDO RMS 2005 VIN CYCLO | 101054812 |
| 160017027 | 160013522 | 0 | 45.7 | null | 2017-05-03 | 2017-05-03 | PEMBROLIZUMAB | 2 | null | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 101416533 |
| 160017029 | 160013523 | 1.56 | 56.15 | Neo-adjuvant (N) | 2019-01-31 | 2019-02-14 | Cisplatin 7 day | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101001269 |
| 160017030 | 160013524 | 1.8 | 92 | Palliative (P) | 2017-07-01 | 2017-08-22 | Pemetrexed | 02 | N | CYCLOPHOSPHAMIDE HIGH DOSE | 101823003 |
| 160017031 | 160013525 | 1.61 | 109.8 | Neo-adjuvant (N) | 2019-05-10 | 2019-05-10 | VINCRISTINE | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100388956 |
| 160017032 | 160013526 | 1.66 | 135 | null | 2017-04-15 | 2017-04-29 | EW EuroEwing 2012 Arm B IE | 01 | null | LAROTRECTINIB | 101275146 |
| 160017043 | 160013527 | 1.72 | 84 | Adjuvant (A) | 2016-06-19 | 2016-10-14 | Ifosfamide | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101658857 |
| 160017044 | 160013528 | 1.69 | 17.5 | Palliative (P) | 2017-08-21 | 2017-08-30 | Doxorubicin + Ifosfamide | 01 | N | CYCLOPHOSPHAMIDE + DACTINOMYCIN + DOXORUBICIN + VINCRISTINE | 101125629 |
| 160017045 | 160013529 | 1.74 | 65 | null | 2019-08-10 | 2019-09-09 | Trial Unspecified | 02 | null | WT SIOP 2002 01 POST OP CARBO, ETOP | 100263234 |
| 160017051 | 160013530 | 1.62 | 61.3 | Palliative (P) | null | 2018-11-16 | NB Low/Intermed risk guidelines CADO | 02 | null | NIRAPARIB | 100887779 |
| 160017052 | 160013531 | 1.68 | 81.2 | Palliative (P) | null | 2017-03-14 | Cyclophosphamide + Vincristine | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100940818 |
| 160017053 | 160013532 | 1.76 | 66.2 | null | 2017-11-18 | 2017-11-26 | ETOP 13-18 BEAT-meso Trial | 02 | null | EW EUROEWING 2012 ARM B VC | 100949152 |
| 160017054 | 160013533 | 0 | 74 | Palliative (P) | 2021-03-01 | 2021-03-01 | Ifosfamide | 02 | N | NOT MATCHED | 101068411 |
| 160017055 | 160013534 | 1.58 | 50.1 | Curative (C) | 2019-12-18 | 2020-01-01 | Olaparib | 02 | N | NIRAPARIB | 100878610 |
| 160017059 | 160013535 | 1.72 | 99.95 | null | 2018-01-03 | 2018-01-14 | GEMCITABINE | 02 | N | GEMCITABINE | 101091479 |
| 160017067 | 160013537 | 0 | 16.5 | null | 2020-09-11 | 2020-09-11 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | null | NIRAPARIB | 100157495 |
| 160017074 | 160013538 | null | null | null | 2018-03-31 | 2018-04-11 | CYCLO + DOXORUBICIN + VINCRISTINE | 02 | null | EW EUROEWING 2012 ARM B VC | 101361211 |
| 160017076 | 160013539 | 1.71 | 96.7 | 03 | 2019-07-16 | 2019-07-18 | VAI (Ifos 3g/m2) | 2 | N | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 101525979 |
| 160017078 | 160013540 | 1.64 | 72.8 | null | 2017-12-22 | 2018-02-04 | Cyclophosphamide + Topotecan | 02 | null | ETOPOSIDE | 101464795 |